248 results about "Whole blood" patented technology

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating triple negative breast cancer and application thereof. The traditional Chinese medicine composition is prepared from the following main active ingredients in parts by mass: 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of rhizoma curcumae, 10 to 20 parts of herba hedyotidis diffusae, 5 to 15 parts of fructus aurantii immaturus, 5 to 15 parts of radix bupleuri, 5 to 15 parts of radix paeoniae alba and 5 to 15 parts of liquorice root. Animal experiments show that the traditional Chinese medicine composition can significantly inhibit tumor growth and pulmonary metastasis of triple-negative breast cancer tumor-bearing mice, increase the proportion of CD8 + T lymphocytes in blood, reduce the proportion of MDSCs, significantly down-regulate the expression of pro-inflammatory cytokines such as IL-6, IL-1alpha, CXCL1 and GM-CSF in serum, and cooperate with PD-L1 immunotherapy to achieve a synergistic effect. And the whole blood and liver and kidney function indexes are in a normal range. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively inhibiting the tumor growth and pulmonary metastasis of the triple negative breast cancer, remodeling the immune state of an organism and reducing the release of proinflammatory factors, and is safe, reliable, free of obvious liver and kidney toxicity and blood toxicity and small in side effect.

Systems, devices, and methods for processing whole blood are disclosed. The system includes a reusable separation device, a disposable fluid circuit, and a controller configured to detect a flow restriction within a leukoreduction filter and to determine the cause of the flow restriction.

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.

The invention relates to the technical field of blood vessel image segmentation, and provides a fundus blood vessel image accurate segmentation method based on a U-Net model, aiming at solving the problem that the existing blood vessel segmentation method based on deep learning is difficult to effectively balance global context and local details. In order to solve the problem of inaccurate blood vessel structure segmentation caused by factors such as poor image quality and low contrast ratio, a method of combining a wavelet and a visual state space model and an adaptive dynamic fusion module is provided to improve the integrity of a slender blood vessel and the structural segmentation accuracy of a complex blood vessel network in a fundus blood vessel image. By integrating multiple efficient feature extraction mechanisms, accurate recognition of small blood vessels and the whole blood vessel structure is achieved, the accuracy and robustness of blood vessel segmentation in complex medical images are remarkably improved, and the method can be widely applied to analysis of eye blood vessels such as retinopathy and hypertensive fundus lesion and research of biomarkers related to the blood vessels.

The invention belongs to the field of disease evolution trajectory prediction in precision medicine, and discloses a Parkinson's disease evolution prediction modeling method based on high-order gene communication tensor. According to the method, firstly, based on an intercellular communication mechanism, a high-order gene module communication tensor is constructed as spatial topological data, so that an information interaction mode between gene modules is described; secondly, a self-adaptive Transform module is designed to extract gene expression features and high-order space topology features at the same time; and finally, integrating multi-view interaction information between the high-order gene module communication tensor and the whole blood transcriptome data through a multi-view collaborative fusion mechanism to realize effective fusion and utilization of features. Experimental results show that compared with a traditional genetic map, the high-order space representation provided by the invention has finer resolution capability, a plurality of evaluation indexes are remarkably improved, and a new technical means is provided for accurate staging of Parkinson's disease.

The disclosed apparatus, systems and methods relate to technology that provides a method for the assessment of the polymerization of a sample, e.g., whole blood or blood plasma coagulation, by a non-contact acoustic tweezing device via the application of a sweeping frequency to the levitating sample and the corresponding assessment of extracted sample parameters.

The present application relates to a kind of detection system and detection method based on microfluidic chip.The detection system based on microfluidic chip includes microfluidic chip for blood detection, centrifugal processing device, chip fluorescence scanning device.The present application also provides the detection method based on the above system.The detection system and detection method provided by the present application have small sample requirement, and the existing blood detection method generally needs 2mL serum (about 4-5mL whole blood) when detecting, the microfluidic chip used in the present application generally only needs 0.3mL whole blood (corresponding to 60 detections).At the same time, with the aid of centrifugal processing device, chip fluorescence scanning device, high-throughput, high-efficiency operation can be realized.

The invention discloses a method for determining a quaternary ammonium salt pesticide in blood by using liquid chromatography-mass spectrometry, which comprises the following steps of: drawing a whole blood (plasma and serum) matrix labeling standard working curve through liquid chromatography-mass spectrometry analysis; obtaining peak areas of quantitative ion peaks of target objects containing paraquat, aquacide, diguat, chlormequat and mepiperidine with different concentrations and peak areas of quantitative ion peaks of internal standard substances, and further drawing a standard working curve; and performing liquid chromatography-mass spectrometry analysis on the whole blood sample under the same condition to obtain the peak area of a target substance quantitative ion peak and the peak area of an internal standard substance quantitative ion peak in the whole blood test solution, and calculating the content of each quaternary ammonium salt pesticide according to the standard working curve. The method can be used for simultaneously detecting the content of five quaternary ammonium salt pesticides in the whole blood of the poisoned patient simply, conveniently and quickly, and has the characteristics of simplicity, accuracy, good repeatability and high sensitivity.

The present application relates to the technical field of biotechnology, and particularly relates to a D-dimer chemiluminescence assay kit. The present application provides a D-dimer chemiluminescence assay kit, which comprises a magnetic particle suspension (immunomagnetic beads) coated with D-dimer antibody 1, alkaline phosphatase-labeled D-dimer antibody 2 (enzyme-labeled antibody) and a calibrant. The immunomagnetic beads and the enzyme-labeled antibody are prepared by chemical coupling and stored in a buffer containing a soluble high molecular material, which can effectively improve the detection sensitivity and repeatability. The kit can be used in combination with a substrate solution containing a chromogenic substrate such as adamantane and its derivative AMPPD or APS-5 for a full-automatic immune test system, and the content of D-dimer in plasma or whole blood can be determined by a chemiluminescence instrument. The kit has high detection sensitivity and good repeatability.

The invention provides an application of a pair of immune costimulatory factors TNFSF9 / TNFRSF9 as markers in preparation of a product for early prediction of preeclampsia, and the immune costimulatory factors comprise a tumor necrosis factor superfamily member 9 (TNFSF9) and a tumor necrosis factor receptor superfamily member 9 (TNFRSF9). The product is used for carrying out early warning on the preeclampsia occurrence risk 20 weeks before pregnancy. The product is used for detecting the immune costimulatory factor through at least one of serum, plasma, whole blood and placental tissue. The invention aims to improve the early prediction efficiency of preeclampsia by detecting the abnormal expression level of the pair of markers.

The application discloses an up-conversion fluorescent probe, an isoniazid detection method and a portable isoniazid detection sensor and belongs to the field of biological detection. The up-conversion fluorescent probe is composed of lanthanide-doped core-shell structure up-conversion nanoparticles subjected to acid pickling treatment and p-dimethylaminobenzaldehyde, wherein the core particle diameter of the up-conversion nanoparticles is 25.85-28.85 nm, and the shell layer thickness is 0.98-1.38 nm. The lanthanide-doped core-shell structure up-conversion nanoparticles are used as an energy donor, and the p-dimethylaminobenzaldehyde is used as a specific recognition molecule, and ratio-type fluorescence detection is realized through an inner filter effect. Isoniazid reacts with DMAAB to generate a Schiff base, which causes fluorescence quenching at 475 nm and no change in 655 nm fluorescence, so that the fluorescence color changes from blue to red. Due to the near-infrared excitation characteristics of the up-conversion nanoparticles, the up-conversion nanoparticles are not easily disturbed by background fluorescence, so that rapid quantitative detection of isoniazid in whole blood is realized, and the detection limit is as low as 2.4 μm. The application is simple in operation, strong in anti-interference and suitable for clinical individualized drug monitoring.

A system for whole blood sampling and separation includes a blood draw device coupled to a catheter assembly, with the blood draw device including a catheter tube, a housing that movably receives the catheter tube, and an advancement member to move the catheter tube between first and second positions, to enable a distal end of the catheter tube to be disposed within or past a distal tip of an indwelling catheter. A blood separation device is attached to the blood draw device to directly receive a blood sample therefrom and comprises a centrifuge-free mechanism configured to separate a plasma or serum sample from the blood sample. A sample collection container is coupled with the separation device and provides a vacuum pressure that draws the blood sample into the separation device, with the separated plasma or serum sample being drawn into the sample collection container.

The application discloses a biomedical test strip detection data analysis method and system based on multiple algorithms. The method comprises the following steps: obtaining related data of a test paper to be detected, wherein the related data comprises T-line related data, B-line related data and C-line related data; verifying whether the lengths of three curves corresponding to the related data are consistent, if not, determining that the detection result is invalid, if yes, analyzing sample adding characteristics to determine whether there is sample adding sequence error or no sample adding; distinguishing sample types according to chromatography speed according to the related data; when the sample type is a whole blood type, calculating the length of a sample type identification point corresponding to three lines, adjusting and cutting off, and if the total length exceeds a set threshold, determining that a hemolysis phenomenon leads to an invalid detection result. The method of the application particularly focuses on processing the hemolysis phenomenon and other user operation related problems, thereby enhancing the reliability and efficiency of the overall detection system.

The present disclosure provides a mutant Taq DNA polymerase and the use thereof. In one embodiment, the mutant Taq DNA polymerase exhibits a DNA polymerase activity in a PCR reaction containing whole blood, high concentration salt or humic acid.

A method for collecting blood components, comprising: separating a first amount of plasma from whole blood; separating a total amount of collectable platelets from whole blood available after separating the first amount of plasma; if the total collection amount after the separation of the total amount of platelets is less than a maximum value adjusted by real-time data related to collection, then separating a second amount of plasma from the whole blood available after the separation of the total amount of platelets, and then separating a total amount of erythrocytes from the whole blood available after the separation of the second amount of plasma; and if the total collection amount is at a maximum adjusted by the real-time data relating to the collection, separating a total amount of red blood cells from the whole blood available after separating the total amount of platelets.

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The utility model relates to an improved biochemical analyzer which comprises a rack, a driving assembly, a bearing part, a reagent disc, a pipetting mechanism and an optical signal detection mechanism, the driving assembly is arranged on the rack, the bearing part is connected to the driving assembly, the bearing part is used for bearing the reagent disc, and the driving assembly is used for driving the reagent disc to rotate along the rack; the reagent disc is arranged on the rack, the pipetting mechanism is arranged on the rack and is used for pipetting liquid in the reagent disc, the optical signal detection mechanism is arranged on the rack on one side of the reagent disc and is used for carrying out optical signal detection on a reagent in the reagent disc or a mixture of the reagent and a sample, and the microscopic mechanism is arranged on the rack and is used for carrying out optical signal detection on the reagent or the mixture of the reagent and the sample. The reagent disc is provided with a circular working area, the circular working area is provided with a plurality of counting chambers, the counting chambers are used for quantitatively accommodating a solution containing visible components, the detection end of the microscopic mechanism faces the circular working area, and the microscopic mechanism is used for carrying out microscopic imaging on the visible components in the counting chambers; when the driving assembly drives the reagent disc to rotate along the rack, any one counting chamber can rotate to the position below the detection end of the microscopic mechanism, and the device has the effect of conveniently detecting samples containing components such as whole blood.

According to the bleeding cage and the blood pump thereof, the blood mixing loss can be reduced, the supporting strength is good, the whole bleeding cage is in a circular tube shape, a far-end opening of the bleeding cage forms a blood inlet, a bleeding opening and a flushing outlet are formed in the outer wall of the bleeding cage, and the bleeding opening and the flushing outlet are formed in the axial direction at intervals. Normal blood pumped by the blood pump flows out from the blood outlet, and flushing fluid flows out from the flushing outlet after flushing the gap, so that energy loss caused by blood mixing is reduced, and the hydraulic performance of the blood pump is improved; the bleeding cage has a certain length in the axial direction, and the bleeding opening and the flushing outlet are arranged at an interval, so that the overall structural strength of the bleeding cage is ensured, and the bleeding cage is prevented from being deformed due to stress; meanwhile, the turbulence influence generated when blood flows through the bleeding cage is reduced, stable rotation of the magnet is improved, and then the rotation stability of the whole blood pump is guaranteed.

The present disclosure relates to a method for white blood cell differential counting using whole blood in a fluid state, and the like. The method of the present disclosure does not include the drying and washing processes used in traditional blood cell analysis to provide a standard for multiple white blood cell analysis, thereby enabling rapid analysis with high repeatability and reproducibility even when large quantities of samples are being processed, and providing accurate test results including the numbers, ratios, and morphological discrimination for each type of white blood cells.

The utility model relates to the technical field of blood sampling devices for large animals, and discloses a sterile blood sampling device for large animals, which comprises a blood sampling needle, a blood sampling main pipe and a plurality of blood sampling branch pipes which are communicated in sequence, a peristaltic pump is arranged on the blood sampling main pipe, the blood sampling main pipe is communicated with a plurality of blood sampling branch pipes through a three-way pipe or a four-way pipe, the tail end of each blood sampling branch pipe is respectively connected with a blood sampling bottle, and a stop valve is arranged on each blood sampling branch pipe. According to the scheme, the peristaltic pump and the blood sampling branch pipes are combined, so that the blood sampling amount of a large animal in the end is ensured, meanwhile, the continuity of collecting blood for different project purposes is effectively improved, and the situation that the whole blood sampling amount is affected by blood coagulation and pipe blockage possibly caused by the fact that blood sampling bottles need to be switched and blood sampling is suspended in the midway is avoided.

The invention discloses a detection method of a portable blood potassium tester and the portable blood potassium tester. The method comprises the steps that a communication mechanism is controlled to be selectively communicated with a cleaning liquid containing bottle, a peristaltic pump is controlled to conduct suction, and a first potential measurement value of an electrode detection mechanism is obtained; the communication mechanism is controlled to selectively communicate with the standard liquid containing bottle, the peristaltic pump is controlled to perform suction, and a second potential measurement value of the electrode detection mechanism is obtained; the communication mechanism is controlled to selectively communicate with the sampling bottle, the peristaltic pump is controlled to perform suction, and a third potential measurement value of the electrode detection mechanism is obtained; and determining the concentration of the target potassium ions in the liquid sample to be measured according to the three potential measurement values. According to the method, the detection result can be quickly obtained, the method can be suitable for scenes such as community medical centers and home detection, trace finger tip whole blood of the patient can be obtained during detection, operation is convenient, the patient can conduct self-detection or relatives assist detection, and therefore the medical cost of the patient is effectively reduced, and the convenience and compliance of blood potassium monitoring of the patient are improved.

A biological sample processing device including a blood filtration module and an extraction module incorporated within a common housing. The blood filtration module has a dual filter structure. The extraction module includes a series of chambers that hold agents to effect any one or more of lysis, binding of target material to capture beads, washing, elution, and / or nucleic acid amplification. Moveable magnets are used to move the beads through the chambers to perform the extraction process. A second magnet-based device for preparing largely pure plasma samples from whole blood in the field.

An assay device as well as a method of use thereof is described. The assay device includes a planar substrate having a top surface and a bottom surface. The assay device further includes one or more flow channels disposed within the planar substrate and extending along a dimension of the planar substrate between the top surface and the bottom surface. The assay device further includes an inlet fluidly coupled to the one or more flow channels and one or more vents fluidly coupled to the one or more channels which are operable to facilitate flow of a liquid sample, such as whole blood through the one or more channels. The one or more flow channels are configured to receive a liquid sample from the inlet and allow flow of the liquid sample.

The invention relates to a method for detecting various forms of arsenide in whole blood based on dry blood spot sampling, and belongs to the technical field of blood arsenide clinical detection. In order to solve the problem that a dry blood spot sampling technology is difficult to accurately quantify in detection of various forms of arsenide in whole blood, the invention provides a method for detecting various forms of arsenide in whole blood based on dry blood spot (DBS) sampling, and the method comprises the following steps: preparing a DBS series mixed standard sample, performing pretreatment, then performing HPLC-HG-AFS detection, and drawing a standard curve equation of AsIII, MMA and DMA; a to-be-detected DBS sample of a subject is subjected to pretreatment and HPLC-HG-AFS detection, peak areas are substituted into the corresponding standard curve equations, and the concentrations of the three arsenide compounds in the to-be-detected DBS sample are measured. According to the method, efficient arsenide extraction in the DBS, precise retention of the original valence state, clear separation of polymorphic baselines and collaborative standard reaching of detection precision improvement are realized, and reliable data support can be provided for clinic.

A method for treating an artificial bone implant with blood, according to the method bone material is placed in a container configured to be filled with blood, wherein the container comprises an opening and a cover configured to cover the opening of the container and a fixed separator that separates a bottom part and an upper part. The separator is provided with holes so that when the container is filled with whole blood, the blood in the bottom part is in full contact with the blood in the upper part, and wherein the bone material is in the upper part, on top of the separator.

The application belongs to the technical field of biological medicine, and particularly relates to application of a detection LGALS2 gene reagent in preparation of a reagent kit for detecting sepsis coagulopathy. The product diagnoses sepsis coagulopathy by detecting the transcription level of the LGALS2 gene in a sample, and when the transcription level of the LGALS2 gene is significantly reduced, the subject has sepsis coagulopathy. The application uses LGALS2 as a biomarker, and through a human experiment verification, the transcription level of peripheral blood LGALS2 of a sepsis coagulopathy patient is significantly lower than that of a patient without sepsis coagulopathy. The transcription level of LGALS2 in whole blood RNA has high specificity and sensitivity in diagnosis and prediction of the risk of sepsis coagulopathy. The LGALS2 gene and the transcription level thereof can be used for preparation of a reagent or a kit for early diagnosis of sepsis coagulopathy, provide reference information for giving individualized intervention treatment, and have important clinical application value and popularization.

The application relates to the technical field of biological medicine, in particular to a alginate / polyethyleneimine composite modified magnetic nano probe and a preparation method and application thereof. The application discloses an alginate / polyethyleneimine composite modified magnetic nano probe, which comprises a composite polymer modified magnetic material and an aptamer connected to the composite polymer modified magnetic material; the composite polymer comprises alginate and polyethyleneimine; the magnetic material in the composite polymer modified magnetic material is Fe3O4 magnetic nano particle; and the aptamer comprises an amino-modified CSV aptamer and / or an amino-modified EpCAM aptamer. The magnetic probe disclosed by the application can sort circulating tumor cells directly in 1 milliliter of patient whole blood without lysing red blood cells, and has high sorting efficiency.

The present application relates to the technical field of content detection, in particular to a method for rapidly detecting the content of hydroxyproline in mouse lung tissue, which comprises the following steps: obtaining the original sampling spectrum of the lung tissue of the mouse to be detected at different preset sampling points, and obtaining a non-lung tissue interference characteristic base matrix containing whole blood characteristics and cartilage characteristics; setting an orthogonal filter operator and determining a lung interstitium characteristic spectrum vector; constructing a reference spectrum vector and determining a relative spectral response factor; constructing a spectral minimum spanning tree and determining a signal contribution weight based on the spectral minimum spanning tree and the relative spectral response factor; generating a whole lung fibrosis synthetic spectrum according to the signal contribution weight and the lung interstitium characteristic spectrum vector, and detecting the content of hydroxyproline based on the whole lung fibrosis synthetic spectrum. The present application considers the non-lung tissue interference containing whole blood characteristics and cartilage characteristics when detecting the content of hydroxyproline, which improves the rationality of the detection of the content of hydroxyproline to a certain extent.

The invention discloses a cell-penetrating peptide CPP137 as well as a compound, a composition and application thereof, and belongs to the technical field of polypeptides. According to the application, a cell-penetrating peptide CPP137 with immune cell selectivity is screened out from a plague bacillus sORF library. The polypeptide not only can be efficiently internalized by THP-1 (M0 type) mononuclear cells, but also can specifically target two key antigen presenting cells, namely primary macrophages and dendritic cells (DC), in a complex human whole blood physiological environment, but is not obviously combined with other blood cell types. Therefore, the cell-penetrating peptide CPP137 is a targeted delivery carrier with great potential, can be used for specifically delivering a therapeutic load to myeloid immune cells, and is used for treating intracellular infection and immune-related diseases or used as a vaccine development platform. Meanwhile, CPP137 can also be used as a specific diagnostic marker or an imaging probe for detecting or tracing pathological states related to macrophages / DC.